K A Krohn

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Novel imaging approaches to head and neck cancer
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Semin Oncol 35:262-73. 2008
  2. ncbi request reprint What is in a number? The FDG lumped constant in the rat brain
    Kenneth A Krohn
    University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 48:5-7. 2007
  3. pmc Challenges in clinical studies with multiple imaging probes
    Kenneth A Krohn
    Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 34:879-85. 2007
  4. ncbi request reprint Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 30:819-26. 2003
  5. ncbi request reprint The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images
    K A Krohn
    Imaging Research Laboratory, University of Washington, Box 356004, Seattle, WA 98195 6004, USA
    Nucl Med Biol 28:477-83. 2001
  6. ncbi request reprint Molecular imaging of hypoxia
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 49:129S-48S. 2008
  7. ncbi request reprint Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors
    M Muzi
    Imaging Research Laboratory, Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Nucl Med Biol 28:107-16. 2001
  8. pmc Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
    Mindy D Szeto
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Cancer Res 69:4502-9. 2009
  9. pmc Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells
    David A Plotnik
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 51:1464-71. 2010
  10. ncbi request reprint Hypoxia imaging-directed radiation treatment planning
    J G Rajendran
    Department of Radiology, University of Washington, Seattle, WA 98195, USA
    Eur J Nucl Med Mol Imaging 33:44-53. 2006

Detail Information

Publications63

  1. pmc Novel imaging approaches to head and neck cancer
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Semin Oncol 35:262-73. 2008
    ....
  2. ncbi request reprint What is in a number? The FDG lumped constant in the rat brain
    Kenneth A Krohn
    University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 48:5-7. 2007
  3. pmc Challenges in clinical studies with multiple imaging probes
    Kenneth A Krohn
    Radiology Department, Molecular Imaging Center, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 34:879-85. 2007
    ..The purpose of this article is to promote a critical discussion within the molecular imaging community because our future value to the overall biomedical community will be in supporting better treatment outcomes rather than in detection...
  4. ncbi request reprint Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 30:819-26. 2003
    ..Receptor binding may be measured directly by a concentration assay or as a pharmacodynamic response variable...
  5. ncbi request reprint The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images
    K A Krohn
    Imaging Research Laboratory, University of Washington, Box 356004, Seattle, WA 98195 6004, USA
    Nucl Med Biol 28:477-83. 2001
    ....
  6. ncbi request reprint Molecular imaging of hypoxia
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 49:129S-48S. 2008
    ..Hypoxia imaging in support of molecular medicine has become an important success story over the last decade and provides a model and some important lessons for development of new molecular imaging probes or techniques...
  7. ncbi request reprint Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors
    M Muzi
    Imaging Research Laboratory, Department of Radiology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Nucl Med Biol 28:107-16. 2001
    ..These results also suggest that a shift from HK I to HK II, which has been observed to increase in brain tumors, would have little effect on the value of the tumor LC...
  8. pmc Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
    Mindy D Szeto
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Cancer Res 69:4502-9. 2009
    ..04). Moreover, highly significant positive correlations were found between biological aggressiveness ratio (rho/D) and both RH (P < 0.00003) and the mean T/B (P < 0.0007)...
  9. pmc Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells
    David A Plotnik
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 51:1464-71. 2010
    ....
  10. ncbi request reprint Hypoxia imaging-directed radiation treatment planning
    J G Rajendran
    Department of Radiology, University of Washington, Seattle, WA 98195, USA
    Eur J Nucl Med Mol Imaging 33:44-53. 2006
    ..As a case example, we review emerging data on PET imaging of hypoxia to direct radiotherapy...
  11. ncbi request reprint Imaging cellular proliferation as a measure of response to therapy
    K A Krohn
    Division of Nuclear Medicine, Imaging Research Laboratory Box 356004, University of Washington, Seattle, WA 98195-6004, USA
    J Clin Pharmacol . 2001
    ..Patient imaging using the PET thymidine analogs is at an earlier stage but appears promising as a clinically feasible approach to cellular proliferation imaging...
  12. ncbi request reprint True tracers: comparing FDG with glucose and FLT with thymidine
    Kenneth A Krohn
    Department of Radiology, University of Washington, Seattle, 98195 6004, USA
    Nucl Med Biol 32:663-71. 2005
    ..The fidelity with which analog tracers mimic tracers of the authentic substrate is critically evaluated for [(18)F]-2-fluoro-2-deoxyglucose and [(18)F]-3'-fluoro-3'-deoxythymidine...
  13. ncbi request reprint [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro
    Robert C Burrows
    Molecular Imaging Research Center, Department of Radiology, University of Washington, 98195, Seattle, WA, USA
    Nucl Med Biol 31:1-9. 2004
    ..The results show that extracellular glucose concentration has a greater impact on the rate of FDG accumulation than the relative abundance of GLUT transporter subtypes...
  14. ncbi request reprint Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
    Lanell M Peterson
    Department of Radiology, University of Washington Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    J Nucl Med 49:367-74. 2008
    ..We therefore compared (18)F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures...
  15. ncbi request reprint Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:145-50. 2002
    ..Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (KTdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results...
  16. ncbi request reprint Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation
    Kevin S Tralins
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington, USA
    J Nucl Med 43:1667-73. 2002
    ..On the basis of these premises, we initiated a pilot study to investigate the use of (18)F-FDG PET for the guidance of radiation dose escalation in the treatment of GBM...
  17. ncbi request reprint The FDG lumped constant in normal human brain
    Michael M Graham
    Division of Nuclear Medicine, Department of Radiology, University of Iowa, Iowa City, Iowa 52242, USA
    J Nucl Med 43:1157-66. 2002
    ..The lumped constant (LC) is a correction factor used to infer glucose metabolic rate (MR(glc)) from FDG metabolic rate (MR(FDG))...
  18. ncbi request reprint [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression
    J G Rajendran
    Department of Radiology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Eur J Nucl Med Mol Imaging 30:695-704. 2003
    ..Identification of hypoxia and development of a more complete biologic profile of STS will serve to guide more rational, individualized cancer treatment approaches...
  19. ncbi request reprint [18F]fluoroestradiol radiation dosimetry in human PET studies
    D A Mankoff
    Departments of Radiology and Medical Oncology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 42:679-84. 2001
    ..FES is a useful estrogen receptor-imaging agent, and the potential radiation risks associated with this study are well within accepted limits...
  20. ncbi request reprint Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
    J Nucl Med 47:1612-21. 2006
    ..Uptake may result from retention in the biosynthetic pathway or leakage via the disrupted blood-tumor barrier. Visual analysis or static measures of 18F-FLT uptake are problematic as transport and retention cannot be distinguished...
  21. ncbi request reprint Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer
    Joseph G Rajendran
    Department of Radiology, University of Washington, Veterans Administration Puget Sound Health Care System, Seattle 98195, USA
    Clin Cancer Res 12:5435-41. 2006
    ..F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer...
  22. ncbi request reprint Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
    Hannah M Linden
    Division of Medical Oncology, School of Medicine, University of Washington Medical Center, Seattle, WA, USA
    Clin Cancer Res 12:5608-10. 2006
  23. ncbi request reprint Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
    ..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
  24. ncbi request reprint [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma
    Gary N Mann
    Department of Surgery, University of Washington, Box 356410, 1959 N E Pacific Street, Seattle, Washington 98195, USA
    Ann Surg Oncol 13:187-97. 2006
    ..We evaluated whether positron emission tomography (PET) scanning with the combination of [18F]fluorodeoxyglucose (FDG) and the norepinephrine analogue [11C]metahydroxyephedrine (mHED) would allow more exact diagnosis and localization...
  25. pmc Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy
    David A Mankoff
    Seattle Cancer Care Alliance, Radiology, 2nd Floor, 825 Eastlake Avenue East, PO Box 19023, Seattle, WA 98109, USA
    Acad Radiol 14:398-405. 2007
  26. ncbi request reprint 18F-Fluoroestradiol
    Lavanya Sundararajan
    Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA
    Semin Nucl Med 37:470-6. 2007
    ..Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight...
  27. ncbi request reprint Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival
    Alexander M Spence
    Department of Neurology, University of Washington, Seattle, Washington 98195, USA
    Clin Cancer Res 14:2623-30. 2008
    ....
  28. ncbi request reprint Tumor receptor imaging
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington, USA
    J Nucl Med 49:149S-63S. 2008
    ....
  29. ncbi request reprint NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies
    Alexander M Spence
    Department of Neurology, University of Washington, Box 356465, 1959 NE Pacific Street, Seattle, WA 98195 6004, USA
    Mol Imaging Biol 10:271-80. 2008
    ..The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity...
  30. pmc Site-specific labeling of annexin V with F-18 for apoptosis imaging
    Xuehe Li
    Department of Radiology, University of Washington Medical Center, Seattle, Washington 98195, USA
    Bioconjug Chem 19:1684-8. 2008
    ..Erythrocyte binding assay of [(18)F]FAN-128 showed that this modification of annexin V-128 did not compromise its membrane binding affinity. Thus, an in vivo investigation of [ (18)F]FAN-128 as an apoptosis imaging agent is warranted...
  31. pmc Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas
    Kristin R Swanson
    Department of Pathology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 50:36-44. 2009
    ..Given the role of hypoxia in upregulating angiogenic factors, we hypothesized that the distribution of hypoxia seen on 18F-FMISO is correlated spatially and quantitatively with the amount of leaky neovasculature seen on T1Gd...
  32. ncbi request reprint NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies
    Alexander M Spence
    Department of Neurology, University of Washington, Mailstop 356465, 1959 NE Pacific Street, Seattle, WA 98195, USA
    Mol Imaging Biol 11:343-55. 2009
    ..The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-D: -glucose (FDG)...
  33. ncbi request reprint Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond
    David A Mankoff
    University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, USA
    Clin Cancer Res 13:3460-9. 2007
    ....
  34. ncbi request reprint [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure
    James G Douglas
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195 6043, USA
    Int J Radiat Oncol Biol Phys 64:886-91. 2006
    ..Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme...
  35. ncbi request reprint Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis
    Kevin J Yagle
    Department of Radiology, Molecular Imaging Laboratory, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 46:658-66. 2005
    ..Because one of the earliest measurable events in apoptosis is the eversion of phosphatidylserine from the inner membrane leaflet to the outer cell surface, annexin V has proven useful for detecting the earliest stages of apoptosis...
  36. ncbi request reprint Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake
    Jeffrey L Schwartz
    Department of Radiation Oncology, University of Washington Medical Center, Box 356069, Seattle, WA 98195 6069, USA
    Nucl Med Biol 31:419-23. 2004
    ..We conclude that a functional p53 response is required to maintain the normal relationship between TK1 activity and S phase percentage following radiation exposure...
  37. ncbi request reprint Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, 98195, USA
    Clin Cancer Res 10:2245-52. 2004
    ..Although acute hypoxia results in accelerated glycolysis, cellular metabolism is slowed in chronic hypoxia, prompting us to look for discordance between FMISO and FDG uptake...
  38. ncbi request reprint Production of [F-18]fluoroannexin for imaging apoptosis with PET
    John R Grierson
    Department of Radiology, University of Washington, Seattle, Washington 91895, USA
    Bioconjug Chem 15:373-9. 2004
    ..F-18]Fluoroannexin should prove useful in imaging targeted apoptosis...
  39. ncbi request reprint Systematic screening of potential beta-cell imaging agents
    Ian R Sweet
    Departments of Medicine, University of Washington, Seattle, WA 98195, USA
    Biochem Biophys Res Commun 314:976-83. 2004
    ..In vivo tests of the biodistribution of glibenclamide and fluorodithizone in rats indicated that the compounds were not specifically associated with pancreas, bearing out the predictions of the in vitro screen...
  40. ncbi request reprint Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs
    Jeffrey L Schwartz
    Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington 98195 6069, USA
    J Nucl Med 44:2027-32. 2003
    ..The goal of this study was to test this hypothesis and determine how well these tracers track changes in proliferation of tumor cells...
  41. ncbi request reprint 18F-Fluorothymidine radiation dosimetry in human PET imaging studies
    Hubert Vesselle
    Department of Radiology, Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    J Nucl Med 44:1482-8. 2003
    ..We estimated the radiation dosimetry for this tracer from data gathered in patient studies...
  42. ncbi request reprint Dynamic perifusion to maintain and assess isolated pancreatic islets
    Ian R Sweet
    Department of Medicine, University of Washington, Seattle 98195, USA
    Diabetes Technol Ther 4:67-76. 2002
    ..The ability to systematically assess the metabolic and functional viability of islets will facilitate the optimization of islet isolation procedures, islet transplantation studies, and islet storage methodologies...
  43. ncbi request reprint 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Clin Cancer Res 8:971-9. 2002
    ..Changes in metabolism between the start and finish of RT, and immediate post-RT studies have received little attention...
  44. ncbi request reprint Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography
    John R Grierson
    Department of Radiology, University of Washington, Seattle, WA 98195 6004, USA
    Nucl Med Biol 31:829-37. 2004
    ..Despite the fact that FLT lacks the 3'-hydroxy necessary for its incorporation into DNA it out performed both FMAU and FIAU in terms of uptake and retention...
  45. ncbi request reprint Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6465, USA
    J Nucl Med 46:274-82. 2005
    ..Compartmental modeling results were compared with simple model-independent methods of estimating FLT uptake...
  46. ncbi request reprint Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies
    Mark Muzi
    Department of Radiology, University of Washington, Seattle, Washington 98195 6465, USA
    J Nucl Med 46:371-80. 2005
    ..The model reflects the retention of FLT-monophosphate (FLTMP), which is generated by the phosphorylation of FLT by thymidine kinase 1 (TK1), the initial step in the exogenous pathway...
  47. ncbi request reprint 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter
    Alexander M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Nucl Med 45:1653-9. 2004
    ....
  48. ncbi request reprint Non-invasive imaging of beta cell mass: a quantitative analysis
    Ian R Sweet
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Diabetes Technol Ther 6:652-9. 2004
    ..However, beta cells constitute only about 1% of pancreatic mass and are distributed throughout the pancreas within tiny islets of Langerhans that are each less than the spatial resolution of non-invasive imaging technologies...
  49. ncbi request reprint PET imaging of cellular proliferation
    David A Mankoff
    Division of Nuclear Medicine, Department of Radiology, University of Washington, 1959 Northeast Pacific Street, Room NN203, Box 356113, Seattle, WA 98195, USA
    Radiol Clin North Am 43:153-67. 2005
    ....
  50. ncbi request reprint Imaging hypoxia and angiogenesis in tumors
    Joseph G Rajendran
    Division of Nuclear Medicine, Department of Radiology, Box 356113, University of Washington, Seattle, WA 98195, USA
    Radiol Clin North Am 43:169-87. 2005
    ....
  51. ncbi request reprint Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma
    J F Eary
    University of Washington Medical Center, Department of Radiology, Seattle 98195 6113, USA
    Nucl Med Biol 24:635-8. 1997
    ..Treatment trials that do not provide dose estimates for critical normal organs are less likely to succeed in identifying a clinical role for radioimmunotherapy...
  52. ncbi request reprint Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis
    Joanne M Wells
    University of Washington, USA
    Mol Imaging 1:151-9. 2002
    ....
  53. ncbi request reprint Evaluation of alternative approaches for imaging cellular growth
    K A Krohn
    Division of Nuclear Medicine, University of Washington, Seattle 98195-6004, USA
    Q J Nucl Med 45:174-8. 2001
    ..Thus imaging with labeled thymidine, which is incorporated into DNA but not into RNA, provides definitive evidence of a cell that is proliferating and, therefore, whether it has responded to treatment...
  54. ncbi request reprint Multinuclear NMR studies of an actively dividing artificial tumor
    E G Shankland
    Department of Radiology, University of Washington, Seattle 98195, USA
    Physiol Res 51:49-58. 2002
    ..These data further suggest that this system will be useful for studying the physiology and biochemistry of exponentially growing cells for at least two days in NMR tube culture...
  55. ncbi request reprint Production of [11C]CH3I by single pass reaction of [11C]CH4 with I2
    J M Link
    Imaging Research Laboratory, UW Medical Center University of Washington, Seattle 98195 6004, USA
    Nucl Med Biol 24:93-7. 1997
    ..The yield of [11C]CH3I was > 50% from [11C]CH4I; its specific activity was 12,000 Ci/mmole. The synthesis takes only 4 min after 11CH4 production and can be repeated without system cleanup...
  56. ncbi request reprint Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model
    Eneida R Nemecek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Clin Cancer Res 11:787-94. 2005
    ..We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans...
  57. ncbi request reprint Molecular imaging of regional brain tumor biology
    A M Spence
    Department of Neurology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Cell Biochem Suppl 39:25-35. 2002
    ..g., epidermal growth factor receptor, that promote or suppress cellular malignant behavior...
  58. ncbi request reprint The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
    ..The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes...
  59. ncbi request reprint Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
    David A Mankoff
    Mol Imaging Biol 5:281-5. 2003
  60. pmc Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme
    Keith J Stelzer
    Celilo Radiation Therapy, Mid Columbia Medical Center, Dalles, OR, USA
    Neuro Oncol 10:88-92. 2008
    ..Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques...
  61. ncbi request reprint Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
    James L Tatum
    National Cancer Institute, Executive Plaza North, Room 6000, 6130 Executive Boulevard, Rockville, MD 20852 7440, USA
    Int J Radiat Biol 82:699-757. 2006
    ....
  62. pmc Imaging oxygenation of human tumours
    Anwar R Padhani
    Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
    Eur Radiol 17:861-72. 2007
    ..We discuss where developments are required for hypoxia imaging to become clinically useful and explore potential new uses for hypoxia imaging techniques including biological conformal radiotherapy...
  63. ncbi request reprint Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?
    William C Eckelman
    The Department of Radiology, University of California, San Diego, 92093 0819, USA
    Nucl Med Biol 32:657-62. 2005
    ..This article explores the possible analogies between current targeted drug development and molecular imaging-targeted probe development with the goal of better defining the path to new molecular imaging probes for the clinic...

Research Grants7

  1. NUCLEAR IMAGING OF TUMORS--BIOLOGICAL AND CHEMICAL BASIS
    Kenneth Krohn; Fiscal Year: 2001
    ..abstract_text> ..
  2. NUCLEAR IMAGING OF TUMORS--BIOLOGICAL AND CHEMICAL BASIS
    Kenneth Krohn; Fiscal Year: 2000
    ..abstract_text> ..
  3. FUNCTIONAL IMAGING & MASS ANALYSIS OF PANCREATIC B CELLS
    Kenneth Krohn; Fiscal Year: 2000
    ....
  4. FUNCTIONAL IMAGING & MASS ANALYSIS OF PANCREATIC B CELLS
    Kenneth Krohn; Fiscal Year: 2001
    ....
  5. Cyclotron for PET Isotope Production
    Kenneth Krohn; Fiscal Year: 2002
    ..This cyclotron will be a productive research tool at UW for at least 20 years, well beyond the lifetime of most high-end instrumentation. ..
  6. FUNCTIONAL IMAGING & MASS ANALYSIS OF PANCREATIC B CELLS
    Kenneth Krohn; Fiscal Year: 2002
    ....
  7. Molecular Imaging and Its Response to Therapy
    Kenneth Krohn; Fiscal Year: 2008
    ..Our goals are ambitious and the methods complex, but our collective effort will make a significant and valuable contribution to oncology. ..